3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
127
Breast Neoplasms
83
Neoplasms
79
Colorectal Neoplasms
68
Neoplasm Metastasis
66
Prostatic Neoplasms
62
Leukemia, Myeloid, Acute
61
Ovarian Neoplasms
58
Recurrence
56
Pancreatic Neoplasms
56
Multiple Myeloma
52
Melanoma
41
Lung Neoplasms
38
Glioblastoma
38
Triple Negative Breast Neoplasms
36
Squamous Cell Carcinoma of Head and Neck
35
Endometrial Neoplasms
33
Lymphoma, Non-Hodgkin
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30
Lymphoma, Large B-Cell, Diffuse
28
Carcinoma, Renal Cell
28
Lymphoma
27
Stomach Neoplasms
26
Small Cell Lung Carcinoma
26
Myelodysplastic Syndromes
26
Carcinoma, Hepatocellular
26
Lymphoma, B-Cell
25
Advanced Solid Tumor
25
Sarcoma
24
Leukemia, Lymphocytic, Chronic, B-Cell
24
Interventions
olaparib
1
lutetium Lu 177 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adrenal Gland Neoplasms
×
90 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled